- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
AbbVie Inc (ABBV)
The AbbVie share price today is 293.30, view NYSE ABBV stock exchange data. Track the latest AbbVie share price with real-time updates on ABBV stock performance including market cap, day range, 52-week range and dividend yield. Access ABBV charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
289.59
294.57
52 wk Range
190.75
302.93
ABBV is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
289.59294.57
52 wk Range
190.75302.93
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ABBV Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
310.65
Upside
+5.92%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
AbbVie stock hits all-time high at 298.74 USD- Investing.com
- AbbVie stock hits all-time high at 298.74 USD
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
23 Buy
5 Hold
1 Sell
Ratings:
29 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 310.65
(+5.92% Upside)
AbbVie Inc SWOT Analysis
Pipeline Powerhouse | Explore AbbVie's robust drug pipeline, featuring promising candidates in late-stage development across multiple therapeutic areas, poised to drive future growth |
Humira's Heir Apparent | Discover how Skyrizi and Rinvoq are exceeding expectations, with combined revenue projections surpassing $31 billion by 2027, offsetting Humira's decline |
Strategic Acquisitions | Learn about AbbVie's recent acquisitions of ImmunoGen and Cerevel, bolstering its oncology and neuroscience portfolios and diversifying revenue streams |
Analyst Optimism | Delve into analyst perspectives, with price targets ranging from $205 to $240, reflecting confidence in AbbVie's ability to navigate challenges and capitalize on opportunities |
AbbVie Inc Earnings Call Summary for Q3/2026
- AbbVie Q3 2026 adjusted EPS of $3.82 beat estimates of $3.74; revenue of $17.4B slightly topped $17.36B forecast with 10.5% operational growth.
- Full-year 2026 guidance raised to $13.95-$13.99 EPS and $67.8B revenue; Q4 outlook set at $18.4B revenue and $3.83-$3.87 EPS.
- SKYRIZI and RINVOQ drove growth with raised targets to $21.8B and $10.3B respectively; neuroscience revenue guidance lifted to $13B.
- Quarterly dividend increased 5.2% to $1.82/share, marking 14th consecutive year of increases; generated $14B free cash flow in nine months.
- HUMIRA biosimilar erosion continues while aesthetics faces pressure; pipeline focus on etentamig and SKYRIZI subcutaneous for Crohn's disease.
Last Updated: 01-11-2026, 02:40 pm
Read Full TranscriptEarnings
Latest Release
30-10-2026
EPS / Forecast
3.82 / 3.74
Revenue / Forecast
17.4B / 17.36B
Compare ABBV to Peers and Sector
Metrics to compare | ABBV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABBVPeersSector | |
|---|---|---|---|---|
P/E Ratio | 50.3x | 25.8x | −0.2x | |
PEG Ratio | 0.15 | −0.46 | 0.00 | |
Price/Book | −113.1x | 1.7x | 2.6x | |
Price / LTM Sales | 7.9x | 3.3x | 2.8x | |
Upside (Analyst Target) | 5.9% | 64.9% | 60.9% | |
Fair Value Upside | Unlock | 4.5% | 9.5% | Unlock |
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the AbbVie (ABBV) Share Price Today?
The AbbVie share price today is 293.30.
What is the current AbbVie (ABBV) share price and day range?
As of 10-11-2026, the AbbVie share price is 293.30, with a previous close of 293.30. The share price has ranged from 289.59 to 294.57 today, while the 52-week range spans from 190.75 to 302.93.
What Is the AbbVie Market Cap?
As of today, AbbVie market cap is 518.44B.
Does AbbVie Pay Dividends? What's The Current Dividend Yield?
The AbbVie dividend yield is 2.5%%.
What Is the AbbVie (ABBV) Share Price Target?
The average 12-month share price target for AbbVie is 310.65, with a high estimate of 350 and a low estimate of 237. 23 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +5.92% Upside potential.
What Is AbbVie's Earnings Per Share (TTM)?
The AbbVie EPS (TTM) is 5.82.
When Is the Next AbbVie Earnings Date?
AbbVie will release its next earnings report on 03-02-2027.
From a Technical Analysis Perspective, Is ABBV a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does AbbVie Trade On?
AbbVie is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for AbbVie?
The stock symbol for AbbVie is "ABBV."
How Many Times Has AbbVie Stock Split?
AbbVie has split 0 times.
How Many Employees Does AbbVie Have?
AbbVie has 57000 employees.
What Is the ABBV Premarket Price?
ABBV's last pre-market stock price is 293.68. The pre-market share volume is 260.00, and the stock has changed by 0.38, or 0.13%.
What Is the ABBV After Hours Price?
ABBV's last after hours stock price is 294.25, the stock has changed by 0.95, or 0.32%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.